Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Clinical Trial
. 2022 Sep 27;328(12):1223-1232.
doi: 10.1001/jama.2022.16464.

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial

Ying Cheng  1 , Liang Han  2 , Lin Wu  3 , Jun Chen  4 , Hongmei Sun  5 , Guilan Wen  6 , Yinghua Ji  7 , Mikhail Dvorkin  8 , Jianhua Shi  9 , Zhijie Pan  10 , Jinsheng Shi  11 , Xicheng Wang  12 , Yuansong Bai  13 , Tamar Melkadze  14 , Yueyin Pan  15 , Xuhong Min  16 , Maksym Viguro  17 , Xingya Li  18 , Yanqiu Zhao  19 , Junquan Yang  20 , Tamta Makharadze  21 , Ekaterine Arkania  22 , Wenying Kang  23 , Qingyu Wang  23 , Jun Zhu  23 ; ASTRUM-005 Study Group
Collaborators, Affiliations
Clinical Trial

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial

Ying Cheng et al. JAMA. .

Abstract

Importance: Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients with extensive-stage small cell lung cancer (SCLC) VSports手机版. It remained unknown whether adding a programmed cell death 1 (PD-1) inhibitor to chemotherapy provided similar or better benefits in patients with extensive-stage SCLC, which would add evidence on the efficacy of checkpoint inhibitors in the treatment of extensive-stage SCLC. .

Objective: To evaluate the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with extensive-stage SCLC. V体育安卓版.

Design, setting, and participants: This international, double-blind, phase 3 randomized clinical trial (ASTRUM-005) enrolled patients at 114 hospital sites in 6 countries between September 12, 2019, and April 27, 2021 V体育ios版. Of 894 patients who were screened, 585 with extensive-stage SCLC who had not previously received systemic therapy were randomized. Patients were followed up through October 22, 2021. .

Interventions: Patients were randomized 2:1 to receive either 4. 5 mg/kg of serplulimab (n = 389) or placebo (n = 196) intravenously every 3 weeks. All patients received intravenous carboplatin and etoposide every 3 weeks for up to 12 weeks. VSports最新版本.

Main outcomes and measures: The primary outcome was overall survival (prespecified significance threshold at the interim analysis, 2-sided P < . 012) V体育平台登录. There were 13 secondary outcomes, including progression-free survival and adverse events. .

Results: Among the 585 patients who were randomized (mean age, 61. 1 [SD, 8. 67] years; 104 [17. 8%] women), 246 (42. 1%) completed the trial and 465 (79. 5%) discontinued study treatment. All patients received study treatment and were included in the primary analyses. As of the data cutoff (October 22, 2021) for this interim analysis, the median duration of follow-up was 12. 3 months (range, 0. 2-24. 8 months). The median overall survival was significantly longer in the serplulimab group (15. 4 months [95% CI, 13. 3 months-not evaluable]) than in the placebo group (10. 9 months [95% CI, 10. 0-14. 3 months]) (hazard ratio, 0. 63 [95% CI, 0. 49-0. 82]; P < . 001). The median progression-free survival (assessed by an independent radiology review committee) also was longer in the serplulimab group (5. 7 months [95% CI, 5. 5-6. 9 months]) than in the placebo group (4. 3 months [95% CI, 4 VSports注册入口. 2-4. 5 months]) (hazard ratio, 0. 48 [95% CI, 0. 38-0. 59]). Treatment-related adverse events that were grade 3 or higher occurred in 129 patients (33. 2%) in the serplulimab group and in 54 patients (27. 6%) in the placebo group. .

Conclusions and relevance: Among patients with previously untreated extensive-stage SCLC, serplulimab plus chemotherapy significantly improved overall survival compared with chemotherapy alone, supporting the use of serplulimab plus chemotherapy as the first-line treatment for this patient population V体育官网入口. .

Trial registration: ClinicalTrials. gov Identifier: NCT04063163. VSports在线直播.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Kang, Q. Wang, and Zhu reported being employees of Shanghai Henlius Biotech, Inc. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Recruitment, Randomization, and Flow of Patients With Extensive-Stage Small Cell Lung Cancer in the ASTRUM-005 Trial
The date of data cutoff was October 22, 2021. aScores range from 0 to 5 (higher scores indicate greater disability). bDetailed reasons appear in eTable 1 in Supplement 2. cPatients received at least 1 dose of study treatment.
Figure 2.
Figure 2.. Kaplan-Meier Estimates of Overall and Progression-Free Survival
Data are from assessments by the independent radiology review committee using version 1.1 of the Response Evaluation Criteria in Solid Tumors. The tick marks indicate censored data. The median duration of follow-up for overall survival at the interim analysis was 12.5 months (IQR, 8.9-15.5 months) for the serplulimab group and 12.3 months (IQR, 8.6-14.9 months) for the placebo group. The median duration of follow-up for progression-free survival was 9.5 months (IQR, 5.6-13.2 months) for the serplulimab group and 8.4 months (IQR, 7.0-13.0 months) for the placebo group. HR indicates hazard ratio; NE, not evaluable.
Figure 3.
Figure 3.. Subgroup Analysis for the Primary Outcome of Overall Survival
The date of data cutoff was October 22, 2021. The hazard ratios (HRs) and P values were not stratified for the patient subgroups and were stratified for the overall population. The median duration of follow-up for overall survival at the interim analysis was 12.5 months (IQR, 8.9-15.5 months) for the serplulimab group and 12.3 months (IQR, 8.6-14.9 months) for the placebo group in the overall population. NR indicates not reached; PD-L1, programmed cell death ligand 1. aFor the patient subgroups, the P values for interaction were calculated by adding treatment, subgroup factor, and a subgroup factor × treatment interaction term into a Cox proportional hazards model. bSelf-reported by the patients by selecting 1 or more racial designations (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Pacific Islander, White, or Other) or based on identity information provided by the patients. All non-Asian patients were White. cEastern Cooperative Oncology Group (ECOG) Performance Status Scale scores range from 0 to 5 (higher scores reflect greater disability). A score of 0 indicates fully active; 1, restricted in physically strenuous activity but ambulatory. dCalculated using a 2-sided stratified log-rank test.
See this image and copyright information in PMC

Comment in

References

    1. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi:10.1038/s41572-020-00235-0 - V体育平台登录 - DOI - PMC - PubMed
    1. American Cancer Society . Cancer facts and figures 2021. Accessed January 10, 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts...
    1. Socinski MA, Smit EF, Lorigan P, et al. . Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27(28):4787-4792. doi:10.1200/JCO.2009.23.1548 - DOI - PubMed
    1. Rossi A, Di Maio M, Chiodini P, et al. . Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692-1698. doi:10.1200/JCO.2011.40.4905 - DOI - PubMed
    1. Goldman JW, Dvorkin M, Chen Y, et al. ; CASPIAN investigators . Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65. doi:10.1016/S1470-2045(20)30539-8 - DOI - PubMed

Publication types

MeSH terms (VSports手机版)

Associated data